ECOG 1808: Randomized phase II trial of sunitinib with or without gemcitabine in advanced kidney cancer with sarcomatoid features.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.4511 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 4511-4511 ◽

Author(s):

Naomi B. Haas ◽

Maneka Puligandla ◽

David F. McDermott ◽

Janice P. Dutcher ◽

Judith Manola ◽

...

Keyword(s):

Kidney Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Randomized Phase Ii

Download Full-text

Sorafenib tosylate for advanced kidney cancer: lucky loser and magic box at the same time

Oncology Reviews ◽

10.4081/oncol.2011.10 ◽

2011 ◽

pp. 141-142

Author(s):

Camillo Porta

Keyword(s):

Kidney Cancer ◽

Treatment Option ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Targeted Agents ◽

Randomized Phase Ii ◽

Molecular Targeted Agents ◽

First Line Treatment

Despite being the very first molecular targeted agents registered for the treatment of advanced kidney cancer (in the post-cytokines setting), Sorafenib seemed to lose its momentum as a credible first-line treatment option, when it proved not to be superior to Interferon within a randomized phase II trial...

Download Full-text

Sorafenib tosylate for advanced kidney cancer: lucky loser and magic box at the same time

Oncology Reviews ◽

10.4081/oncol.2011.141 ◽

2011 ◽

Vol 5 (3) ◽

pp. 141

Author(s):

Camillo Porta

Keyword(s):

Kidney Cancer ◽

Treatment Option ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Targeted Agents ◽

Randomized Phase Ii ◽

Molecular Targeted Agents ◽

First Line Treatment

Despite being the very first molecular targeted agents registered for the treatment of advanced kidney cancer (in the post-cytokines setting), Sorafenib seemed to lose its momentum as a credible first-line treatment option, when it proved not to be superior to Interferon within a randomized phase II trial...

Download Full-text

1400: A Randomized Phase II Trial Evaluating the Importance of Early Erectile Dysfunction Rehabilitation and Unilateral Autologous Sural Nerve Grafting in Patients Undergoing a Unilateral Cavernous Nerve Sparing Radical Prostatectomy for Clinically localized PR

The Journal of Urology ◽

10.1016/s0022-5347(18)31601-x ◽

2007 ◽

Vol 177 (4S) ◽

pp. 461-461 ◽

Author(s):

Christopher G. Wood ◽

David Chang ◽

Run Wang ◽

Yu Shen ◽

Curtis A. Pettaway ◽

...

Keyword(s):

Erectile Dysfunction ◽

Radical Prostatectomy ◽

Phase Ii ◽

Sural Nerve ◽

Phase Ii Trial ◽

Nerve Sparing ◽

Nerve Grafting ◽

Cavernous Nerve ◽

Randomized Phase Ii

Download Full-text

RANDOMIZED PHASE II TRIAL OF CARBOPLATIN-PACLITAXEL COMPARED TO CARBOPLATIN-PACLITAXEL-TRASTUZUMAB IN ADVANCED (STAGE III-IV) OR RECURRENT UTERINE SEROUS CARCINOMA: RESULTS OF INTERIM ANALYSIS (NCT01367002)

10.26226/morressier.5770e29bd462b80290b4bae3 ◽

2016 ◽

Author(s):

Alessandro D Santin

Keyword(s):

Phase Ii ◽

Interim Analysis ◽

Phase Ii Trial ◽

Stage Iii ◽

Serous Carcinoma ◽

Advanced Stage ◽

Randomized Phase Ii ◽

Uterine Serous Carcinoma

Download Full-text

Faculty Opinions recommendation of A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717697918.793457734 ◽

2012 ◽

Author(s):

Hans-Joachim Schmoll

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

Faculty of 1000 evaluation for Automated sedation outperforms manual administration of propofol and remifentanil in critically ill patients with deep sedation: a randomized phase II trial.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.717969496.793472190 ◽

2013 ◽

Author(s):

Andreas Hoeft

Keyword(s):

Critically Ill ◽

Phase Ii ◽

Critically Ill Patients ◽

Phase Ii Trial ◽

Deep Sedation ◽

Randomized Phase Ii

Download Full-text

Faculty Opinions recommendation of PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718144304.793486590 ◽

2013 ◽

Author(s):

Roberto Angioli

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Pegylated Liposomal Doxorubicin ◽

Platinum Resistant ◽

Randomized Phase Ii

Download Full-text

Faculty Opinions recommendation of HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718151420.793488671 ◽

2013 ◽

Author(s):

Brian Keith Bednarski

Keyword(s):

Rectal Cancer ◽

High Risk ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Trial ◽

Randomized Phase Ii

Download Full-text

Faculty Opinions recommendation of Randomized phase II trial of ridaforolimus in advanced endometrial carcinoma.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725563727.793527269 ◽

2017 ◽

Author(s):

Paola Gehrig

Keyword(s):

Endometrial Carcinoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Randomized Phase Ii

Download Full-text

Randomized Phase II Trial of Adjuvant WT-1 Analog Peptide Vaccine in Patients with Malignant Pleural Mesothelioma after Completion of Multimodality Therapy

10.21236/ada566780 ◽

2012 ◽

Author(s):

Lee M. Krug

Keyword(s):

Phase Ii ◽

Malignant Pleural Mesothelioma ◽

Phase Ii Trial ◽

Peptide Vaccine ◽

Multimodality Therapy ◽

Pleural Mesothelioma ◽

Randomized Phase Ii ◽

Download Full-text